PHENOL,2,2'-SULFONYLBIS[3,4,6-TRICHLORO]-

p38 MAP Kinase Inhibitor IV is an ATP-competitive p38α/β MAPK inhibitor.

p38 MAP Kinase Inhibitor IV has been used for blocking p38α kinase activation in order to examine if HOXB7 is involved in the regulation of migration and proliferation process via AKT/MAPK signaling.

A cell-permeable symmetrical sulfone compound that acts as a potent and ATP-competitive inhibitor of p38α/β MAPK (IC₅₀ = 130 and 550 nM, respectively), while exihibiting much reduced activity (≤23% inhibition at 1 μM) against p38γ/δ, ERK1/2, and JNK1/2/3. Shown to be more effective than SB 203850 (Cat. Nos. 559389, 559395, and 559398) in inhibiting LPS-induced IL-1β release from hPBMC (100% vs. 50% inhibition with 100 μM respective inhibitor).

p38 MAP Kinase Inhibitor IV is an ATP-competitive inhibitor of p38α/β MAPK with IC50 values of 130 nM for p38α and 550 nM for p38β. It is much less active with ≤23% inhibition at 1 μM against p38γ/σ, ERK1/2, and JNK1/2/3. Shown to be more effective than SB 203580 in inhibiting LPS-induced IL-1β release from hPBMC (100% vs. 50% inhibition with 100 μM inhibitor). A recent study showed that p38 MAP Kinase Inhibitor IV could consistently and significantly enhance reprogramming and iPS cell generation from somatic cells.

p38α: 0.13 μM (IC₅₀); p38β: 0.55 μM (IC₅₀); p38δ: 8.63 μM (IC₅₀); p38χ: 5.47 μM (IC₅₀)